By AGORACOM Staff

In an exciting development for the world of healthcare and artificial intelligence (AI), Empower Clinics, a leading healthcare company, has announced a groundbreaking achievement: the award of its first clinical trial by a global Fortune 500 pharmaceutical company with a market cap exceeding a staggering $100 Billion. This achievement signifies a significant milestone for Empower Clinics, underlining its growing influence in the intersection of healthcare and AI. In this article, we will delve into the details of this remarkable accomplishment, its implications for the company, and why it's worth taking note of Empower Clinics.

A Pioneering Company at the Confluence of Healthcare and AI

Empower Clinics, led by CEO Steve McAuley, is a healthcare company with a strong focus on the integration of artificial intelligence (AI) and healthcare clinical trials. They have set themselves apart with a dedicated R&D clinical trials division, featuring two clinical research sites and six principal investigators. Beyond this, the company operates as a Site Management Organization (SMO), working with multiple clinical trials concurrently.

Empower Clinics' ambition goes beyond managing trials; they are now on the path to creating a dedicated healthcare AI spin-out. This subsidiary is set to revolutionize patient identification, recruitment, and onboarding processes for clinical trials. Their strategic timing couldn't be better, given the Fortune Business Insight projection that the global clinical trials market will exceed $95 billion by 2030.

Empower Clinics' CEO, Steve McAuley, Speaks on the Achievement

However, this achievement didn't happen overnight; it's the culmination of meticulous planning, thorough industry research, and strategic decision-making. McAuley emphasizes the significance of this moment, signaling a pivotal shift in the company's trajectory.

Unpacking the Value of the Clinical Trial

Preliminary Patient Recruitment Target

Empower Clinics has set an initial patient recruitment target of 20 to 35 patients. These patients will mainly be drawn from the existing patient roster, particularly from the principal investigator in Dallas. But what does this mean in terms of tangible value for Empower Clinics over the next year?

Calculating the Potential Revenue

Empower Clinics' revenue generation is directly linked to patient recruitment. Each patient recruited into an active study represents an annualized value, defined by a contract with the pharmaceutical sponsor. This contract details every interaction, from visits to lab results, with a specific compensation associated with each activity.

Depending on the trial type, stage, and duration, the annualized patient value can range from $30,000 at the lower end to $75,000 or more. Considering the extended duration of trials, which often includes follow-up periods, and the staggered entry of patients, it's clear that the revenue stream for Empower Clinics will be both substantial and sustained.

In the case of the COPD (Chronic Obstructive Pulmonary Disease) study, the company expects to be actively involved for approximately 24 months. This extended period will lead to ongoing monthly, quarterly, and annual revenue streams. While the initial patient recruitment target is 20 to 35, the potential for more patients is unlimited, ensuring a promising revenue outlook.

A Positive Outlook for the Future

Empower Clinics is not resting on this single achievement. Steve McAuley shared that they continue to process multiple trial applications on behalf of their six current principal investigators. This activity anticipates additional due diligence, site visits, and, hopefully, more awards.

This first award from a Fortune 500 pharmaceutical company adds a crucial layer of third-party validation. It builds Empower Clinics' reputation and credibility within the industry, paving the way for further opportunities. Clinical trials are highly competitive, and this award signifies that Empower Clinics has not only entered the arena but is making an impact.

Addressing Skepticism and Looking Ahead

Acknowledging the challenges and skepticism that have plagued the company in recent months, Steve McAuley is resolute in his commitment to this new direction. He acknowledges that the path hasn't been easy but emphasizes the importance of optimism. He invites shareholders and investors to be patient and to look at this as a new opportunity.

The Road Ahead for Empower Clinics

Empower Clinics is on a journey to establish itself as a significant player in the clinical trials space. With a clear focus on AI and healthcare, backed by a robust portfolio of trials, the company is well-positioned to deliver substantial value to its shareholders. The commitment to high-quality trials and patient recruitment, coupled with an expanding network of principal investigators, positions Empower Clinics for a promising future.

In conclusion, Empower Clinics' achievement of securing a clinical trial from a Fortune 500 pharmaceutical company marks a turning point in its journey. As the company continues to garner attention and recognition in the industry, the prospects for revenue generation and growth are highly promising. Investors and stakeholders would be wise to keep a close eye on this dynamic company as it carves out its niche in the healthcare and AI landscape.

YOUR NEXT STEPS 

Visit $EPW HUB On AGORACOM: https://agoracom.com/ir/EmpowerClinics

Visit $EPW 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/EmpowerClinics/profile

Visit $EPW Official Verified Discussion Forum On AGORACOM: https://agoracom.com/ir/EmpowerClinics/forums/discussion

DISCLAIMER AND DISCLOSURE 

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

If you have any questions, please direct them to info@agoracom.com 

For our full website disclaimer, please visit  https://agoracom.com/terms-and-conditions